Development of Novel Physiological CMR Methods in Health and Disease

Coronary Artery Disease Clinical Trial

Official title:

Development of Novel Physiological CMR Methods in Health and Disease

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03854071
• Other study ID #: STH20184
• Status: Suspended
• Phase: N/A
• Start date: July 30, 2018
• Est. completion date: May 1, 2026

Study information

• Verified date: November 2023
• Source: Sheffield Teaching Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Physiological cardiovascular stress test plays a crucial role in the assessment of patients with suspected heart disease. There are several methods of cardiac physiological stress tests and each of them offer varied insight into cardiac physiological adaptation: passive leg raise, intra-venous fluid challenge, pharmacological stressors and physical exercise stress test. Echocardiography, which is the mainstay for the non-invasive rest/stress assessment of the left ventricular (LV) haemodynamics has several limitations. Novel methods of CMR imaging allow to map intra-cardiac flow in three-dimension using novel flow acquisitions. These novel flow acquisitions are called four-dimensional flow CMR, where the fourth dimension is time. Additionally, traditional cine CMR imaging for functional assessment can now be done without breath-holds using advanced acceleration methods, allowing them to be used during exercise. A comprehensive understanding of functional-flow coupling at rest, during increased pre-load (fluid challenge) to the heart or during exercise, is lacking in the literature. There is an important need to validate these novel CMR methods for developing mechanistic insight into physiological cardiac adaptation to increased pre-load or to exercise in health and how it alters in heart disease.

Description:

For this study, the investigators will perform comprehensive physiological CMR in healthy volunteers and patients with suspected or known heart disease (coronary artery disease and heart failure). A sub-set of patients will have follow-up scans after they receive treatment to investigate the therapeutic target role of these physiological CMR metrics. Patients who have given informed consent for this research will receive one physiological stress test depending on the clinical context. There will be 5 clinical subgroups to which patients will be recruited to: Group 1. Heart failure with preserved ejection fraction (HFpEF), Group 2. Heart failure with reserved ejection fraction (HFrEF), Group 3. Pulmonary hypertension (PH), Group 4. Acute myocardial infarction (AMI) and Group 5. Suspected but not treated coronary artery disease (sCAD). Patients will be selected in each group by the clinical specialist/research team as per the published guidelines and local protocols - Group 1 and 2 (19), Group 3 (20), Group 4 (21) and Group 5 (22). First 4 groups of patients will receive pre-load increasing stress test (either passive leg raise or equivalent 500mls intravenous fluid challenge depending on the tolerability). This will be done to investigate if increase in pre-load will help unravel subtle dysfunction which is not apparent at euvolemic state. AMI patients may also receive ischaemia testing stress CMR depending on the main clinically question needed to answer. Patients with sCAD will receive clinically relevant pharmacological stress test (dobutamine, adenosine or regadenoson, inhaled nitric oxide) to diagnose ischaemia. Healthy volunteers who have given informed consent will receive matched physiological stress test so that head-on comparison can be made with the relevant patient cohort. The CMR scan protocol will involve minimal breath-holds and will be patient-friendly. This is achieved by using accelerated, advanced cine and late gadolinium enhancement (LGE)-imaging techniques which require fewer breath-holds and shorter scan. All CMR stress studies will be supervised by an Advanced Life Support (ALS) certified doctor. The CMR protocol for healthy volunteers will include the following components (45 minutes): 1. Survey 2. Baseline cine imaging for functional imaging (rest) 3. Tissue characterisation with native T1-mapping (rest) 4. 4D flow CMR (rest) 5. Record blood pressure, heart rate and oxygen saturation 6. Start of physiological stress (increase pre-load or pharmacological stressors) 7. 4D flow CMR (stress, at low-moderate intensity exercise aiming for heart rate up to 110bpm only) 8. Functional cines (stress, at low-moderate intensity exercise aiming for heart rate up to 110bpm only) 9. Record blood pressure, heart rate and oxygen saturation 10. First pass perfusion imaging (only if adenosine/regadenoson used for myocardial hyperaemia) 11. Record blood pressure, heart rate and oxygen saturation 12. Gadolinium contrast injection 13. Early/Late gadolinium enhancement imaging in short-axis 14. Post contrast T1-mapping End of study For patient's receiving clinical CMR scans, the 'bolt-on' stress CMR protocol will include the following components (20-25minutes): 1. 4D flow CMR (rest) 2. Record blood pressure, heart rate and oxygen saturation 3. Start of physiological stress (increase pre-load or pharmacological stressors) 4. 4D flow CMR (stress, at low-moderate intensity exercise aiming for heart rate up to 110bpm only) 5. Functional cines (stress, at low-moderate intensity exercise aiming for heart rate up to 110bpm only) 6. Record blood pressure, heart rate and oxygen saturation 7. First pass perfusion imaging (only if adenosine/regadenoson used for myocardial hyperaemia) 8. Record blood pressure, heart rate and oxygen saturation

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 150
• Est. completion date: May 1, 2026
• Est. primary completion date: November 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Healthy Volunteers age 20 to 80, recruited from Sheffield Teaching Hospitals staff members
• Patients age 20 to 80 with suspected or known heart disease (group 1 to 5)
• Capable of giving written informed consent

Exclusion Criteria:

• Inability to perform the study protocol secondary to severe heart failure requiring IV therapy
• Patients recruited in the suspected CAD and acute myocardial infarction arms of the study and in need for detection of ischaemia should not have any past medical history of MI, ACS or cardiomyopathy
• Patients with significant valvular heart disease will be excluded from any patient group
• Patient with in atrial fibrillation will be excluded
• Contraindication to MRI (as per standard MRI screening questionnaire issued to patients prior to clinical MRI procedures)

Related Conditions & MeSH terms

• Coronary Artery Disease
• Heart Failure
• Hypertension, Pulmonary
• Infarction
• Myocardial Infarction
• Pulmonary Hypertension

Intervention

Other:
• intravenous fluid challenge
Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability

Locations

Country	Name	City	State
United Kingdom	Sheffield Teaching Hospitals NHS FT	Sheffield	England

Sponsors (1)

Lead Sponsor	Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (24)

Carlsson M, Toger J, Kanski M, Bloch KM, Stahlberg F, Heiberg E, Arheden H. Quantification and visualization of cardiovascular 4D velocity mapping accelerated with parallel imaging or k-t BLAST: head to head comparison and validation at 1.5 T and 3 T. J Cardiovasc Magn Reson. 2011 Oct 4;13(1):55. doi: 10.1186/1532-429X-13-55. — View Citation

Crandon S, Elbaz MSM, Westenberg JJM, van der Geest RJ, Plein S, Garg P. Clinical applications of intra-cardiac four-dimensional flow cardiovascular magnetic resonance: A systematic review. Int J Cardiol. 2017 Dec 15;249:486-493. doi: 10.1016/j.ijcard.2017.07.023. Epub 2017 Sep 28. — View Citation

Eriksson J, Bolger AF, Ebbers T, Carlhall CJ. Four-dimensional blood flow-specific markers of LV dysfunction in dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2013 May;14(5):417-24. doi: 10.1093/ehjci/jes159. Epub 2012 Aug 8. — View Citation

Eriksson J, Dyverfeldt P, Engvall J, Bolger AF, Ebbers T, Carlhall CJ. Quantification of presystolic blood flow organization and energetics in the human left ventricle. Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2135-41. doi: 10.1152/ajpheart.00993.2010. Epub 2011 Mar 18. — View Citation

Franke A. The stress echo dilemma: time counts, but image quality too. Eur Heart J. 2006 Jul;27(14):1646-7. doi: 10.1093/eurheartj/ehl091. Epub 2006 Jun 16. No abstract available. — View Citation

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. No abstract available. — View Citation

Garg P, Westenberg JJM, van den Boogaard PJ, Swoboda PP, Aziz R, Foley JRJ, Fent GJ, Tyl FGJ, Coratella L, ElBaz MSM, van der Geest RJ, Higgins DM, Greenwood JP, Plein S. Comparison of fast acquisition strategies in whole-heart four-dimensional flow cardiac MR: Two-center, 1.5 Tesla, phantom and in vivo validation study. J Magn Reson Imaging. 2018 Jan;47(1):272-281. doi: 10.1002/jmri.25746. Epub 2017 May 4. — View Citation

Ie EH, Vletter WB, ten Cate FJ, Nette RW, Weimar W, Roelandt JR, Zietse R. Preload dependence of new Doppler techniques limits their utility for left ventricular diastolic function assessment in hemodialysis patients. J Am Soc Nephrol. 2003 Jul;14(7):1858-62. doi: 10.1097/01.asn.0000072745.94551.fc. — View Citation

Kanski M, Arvidsson PM, Toger J, Borgquist R, Heiberg E, Carlsson M, Arheden H. Left ventricular fluid kinetic energy time curves in heart failure from cardiovascular magnetic resonance 4D flow data. J Cardiovasc Magn Reson. 2015 Dec 20;17:111. doi: 10.1186/s12968-015-0211-4. — View Citation

Kheradvar A, Assadi R, Falahatpisheh A, Sengupta PP. Assessment of transmitral vortex formation in patients with diastolic dysfunction. J Am Soc Echocardiogr. 2012 Feb;25(2):220-7. doi: 10.1016/j.echo.2011.10.003. Epub 2011 Nov 17. Erratum In: J Am Soc Echocardiogr. 2012 May;25(5):493. — View Citation

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33(14):1787-847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19. No abstract available. Erratum In: Eur Heart J. 2013 Jan;34(2):158. — View Citation

Mertes H, Sawada SG, Ryan T, Segar DS, Kovacs R, Foltz J, Feigenbaum H. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients. Circulation. 1993 Jul;88(1):15-9. doi: 10.1161/01.cir.88.1.15. — View Citation

Monmeneu Menadas JV, Lopez-Lereu MP, Estornell Erill J, Garcia Gonzalez P, Igual Munoz B, Maceira Gonzalez A. Pharmacological stress cardiovascular magnetic resonance: feasibility and safety in a large multicentre prospective registry. Eur Heart J Cardiovasc Imaging. 2016 Mar;17(3):308-15. doi: 10.1093/ehjci/jev153. Epub 2015 Jun 23. — View Citation

Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016 Apr;29(4):277-314. doi: 10.1016/j.echo.2016.01.011. No abstract available. — View Citation

Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation. 2017 Feb 28;135(9):825-838. doi: 10.1161/CIRCULATIONAHA.116.024822. Epub 2016 Dec 30. — View Citation

Pedrizzetti G, La Canna G, Alfieri O, Tonti G. The vortex--an early predictor of cardiovascular outcome? Nat Rev Cardiol. 2014 Sep;11(9):545-53. doi: 10.1038/nrcardio.2014.75. Epub 2014 Jun 3. — View Citation

Sharifov OF, Schiros CG, Aban I, Denney TS, Gupta H. Diagnostic Accuracy of Tissue Doppler Index E/e' for Evaluating Left Ventricular Filling Pressure and Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2016 Jan 25;5(1):e002530. doi: 10.1161/JAHA.115.002530. Erratum In: J Am Heart Assoc. 2016;5(5). pii: e002078. doi: 10.1161/JAHA.116.002078. — View Citation

Task Force Members; Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines; Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers; Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. No abstract available. Erratum In: Eur Heart J. 2014 Sep 1;35(33):2260-1. — View Citation

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Thygesen K, Alpert JS, White HD; Biomarker Subcommittee; Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA; ECG Subcommittee; Chaitman BR, Clemmensen PM, Johanson P, Hod H; Imaging Subcommittee; Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ; Classification Subcommittee; Fox KA, Atar D, Newby LK, Galvani M, Hamm CW; Intervention Subcommittee; Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J; Trials & Registries Subcommittee; Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML; Trials & Registries Subcommittee; Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G; Trials & Registries Subcommittee; Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D; Trials & Registries Subcommittee; Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG); Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers; Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98. doi: 10.1016/j.jacc.2012.08.001. Epub 2012 Sep 5. No abstract available. — View Citation

van der Geest RJ, Garg P. Advanced Analysis Techniques for Intra-cardiac Flow Evaluation from 4D Flow MRI. Curr Radiol Rep. 2016;4:38. doi: 10.1007/s40134-016-0167-7. Epub 2016 May 20. — View Citation

Watanabe H, Sugiura S, Hisada T. The looped heart does not save energy by maintaining the momentum of blood flowing in the ventricle. Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2191-6. doi: 10.1152/ajpheart.00041.2008. Epub 2008 Mar 7. — View Citation

Westenberg JJ, Roes SD, Ajmone Marsan N, Binnendijk NM, Doornbos J, Bax JJ, Reiber JH, de Roos A, van der Geest RJ. Mitral valve and tricuspid valve blood flow: accurate quantification with 3D velocity-encoded MR imaging with retrospective valve tracking. Radiology. 2008 Dec;249(3):792-800. doi: 10.1148/radiol.2492080146. Epub 2008 Oct 10. — View Citation

Wong J, Chabiniok R, deVecchi A, Dedieu N, Sammut E, Schaeffter T, Razavi R. Age-related changes in intraventricular kinetic energy: a physiological or pathological adaptation? Am J Physiol Heart Circ Physiol. 2016 Mar 15;310(6):H747-55. doi: 10.1152/ajpheart.00075.2015. Epub 2016 Jan 8. — View Citation

Zhou BY, Xie MX, Wang J, Wang XF, Lv Q, Liu MW, Kong SS, Zhang PY, Liu JF. Relationship between the abnormal diastolic vortex structure and impaired left ventricle filling in patients with hyperthyroidism. Medicine (Baltimore). 2017 Apr;96(17):e6711. doi: 10.1097/MD.0000000000006711. — View Citation

* Note: There are 24 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	4D CMR Flow	The primary outcome measures will include 4D flow CMR derived mitral inflow diastolic parameter: E/A ratio. This parameter will be quantified once both at rest and during physiological stress.	Through study completion, average 5 years
Secondary	Secondary 4D CMR Flow	Other 4D flow CMR derived outcome metrics will include mitral, tricuspid and pulmonary valve flow quantification - net forward flow (mls), E-velocity (cm/sec), E-velocity deceleration time (msec, both for mitral and tricuspid), A-velocity (cm/sec) and valvular regurgitation (mls).	Through study completion, average 5 years
Secondary	Volumetric and functional parameters	2) Right and left heart volumetric and functional parameters: end-diastolic and end-systolic volumes; ejection fraction	Through study completion, average 5 years